GEOFREY BASALIRWA

Mr. GEOFREY BASALIRWA

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
YWYan Wang
Yan Wang
AWAriana Waters
Ariana Waters
GBGEOFREY BASALIRWA
GEOFREY BASALIRWA
ASAli Ssetaala
Ali Ssetaala
JMJuliet Mpendo
Juliet Mpendo
SKSylvia Kiwuwa-Muyingo
Sylvia Kiwuwa-Muyingo
Objective: Schistosoma mansoni (S. mansoni) infection is endemic in fishing communities. We investigated its potential impact on Hepatitis B (Hep B) vaccine responses and its role in mediating the association between the gut microbiome and the long-term effectiveness of the vaccine response. Methods: Participants were tested for S. mansoni infections at baseline and received the Hep B vaccine at baseline, month 1, and month 6. Those with infections were treated. Stool samples were collected at baseline and analyzed using 16S rRNA sequencing. The Wilcoxon rank-sum test was used to compare alpha diversity between groups. A linear regression model was applied to estimate the association between one-year Hep B vaccine responses and baseline gut microbiome by infection status, adjusting for age and sex. Results: A total of 107 participants were included (44 from the fishing community and 63 from the Kampala community). There was no significant difference in microbiome composition by location or infection status at baseline or exit. In the linear regression analysis, S. mansoni infection (β = 1.24, p = 0.025) and higher alpha diversity (β = 0.001, p = 0.07) were associated with higher Hep B vaccine responses, while older age was associated with a lower Hep B vaccine response (β = -0.06, p = 0.0013). Conclusions: S. mansoni infection status before vaccination may modify the association between the gut microbiome and Hep B vaccine response. Potential interventions could focus on infection control as well as improving microbiome richness before implementing vaccine programs in fishing communities.

31 March 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
YWYan Wang
Yan Wang
AWAriana Waters
Ariana Waters
GBGEOFREY BASALIRWA
GEOFREY BASALIRWA
ASAli Ssetaala
Ali Ssetaala
JMJuliet Mpendo
Juliet Mpendo
SKSylvia Kiwuwa-Muyingo
Sylvia Kiwuwa-Muyingo
Objective: Schistosoma mansoni (S. mansoni) infection is endemic in Ugandan fishing communities. We investigated its potential impact on Hepatitis B (Hep B) vaccine responses and its role in mediating the association between the gut microbiome and long-term effectiveness of the vaccine. Methods: Participants were tested for S. mansoni infections at baseline and received the Hep B vaccine at baseline, month 1, and month 6. Those with infections were treated. Stool samples were collected at baseline and analyzed using 16S rRNA sequencing. The Wilcoxon rank-sum test was used to compare alpha diversity between groups. A linear regression model was applied to estimate the association between one-year Hep B vaccine responses and the baseline gut microbiome by infection status, adjusting for age and sex. Results: A total of 107 participants were included (44 from the fishing community and 63 from the Kampala community). There was no significant difference in microbiome composition by location or infection status at baseline or discharge. In the linear regression analysis, S. mansoni infection (β = 1.24, p = 0.025) and a higher alpha diversity (β = 0.001, p = 0.07) were associated with higher Hep B vaccine responses, while older age was associated with a lower Hep B vaccine response (β = −0.06, p = 0.0013). Conclusions: S. mansoni infection status before vaccination may modify the association between the gut microbiome and Hep B vaccine response. Potential interventions could focus on infection control as well as improving microbiome richness before implementing vaccine programs in fishing communities.

22 October 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
NKNasimu Kyakuwa
Nasimu Kyakuwa
ASAli Ssetaala
Ali Ssetaala
MPMatt A. Price
Matt A. Price
Annet NanvubyaAnnet Nanvubya
Annet Nanvubya
JAJoel Muwanguzi Abyesiza
Joel Muwanguzi Abyesiza
MKMonica Kuteesa
Monica Kuteesa
Background: Vaccine hesitancy (VH) remains a major threat to global health that can reverse the progress in tackling vaccine-preventable diseases. Vaccine uptake among adolescent Girls and young women (AGYW) is often low. We assessed VH using a validated scale among AGYW in Uganda, Zambia, and South Africa. Methods: From June 2023 to February 2024, we recruited AGYW from fishing communities in Uganda, urban and peri-urban locations in Lusaka and Ndola, Zambia, and mining communities in Rustenburg, South Africa. Eligible participants were aged 15–24 years, sexually active, and HIV-negative but at risk for HIV acquisition. We collected demographic, HIV-related behavioral data, and vaccine hesitancy data using a structured questionnaire. Vaccine confidence was assessed using the 10-question Vaccine Hesitancy Scale that describes two factors, i.e., “vaccine confidence” and “risk tolerance”. Exploratory and Confirmatory Factor Analyses were performed to assess scale validity and internal consistency. Logistic regression was used to determine associations between demographics and vaccine confidence. Results: A total of 1213 AGYW participated in the study, with a mean age of 19.4 (SD ± 2.6) years. More than half (54%) were aged between 15 and 19 years. The majority of AGYW (94%) strongly believed that vaccines were important for their health and the community and that vaccination is a good way to protect them from diseases. About two-thirds of the AGYW (66%) indicated that they were concerned about the adverse effects of vaccines, while 30% responded that they did not need vaccines for diseases that were not common. We observed that 951 (78%) of the AGYW reported high vaccine confidence, while 494 (41%) reported low concerns over risks. Vaccine confidence varied across countries, with Zambia and Uganda showing lower vaccine confidence (adjusted odds ratios of 0.28 and 0.45, respectively, p < 0.005) in comparison to South Africa. Conclusions: A high level of vaccine confidence was observed among AGYW. Vaccine confidence among AGYW was driven more by the trust in vaccine safety and the need to protect communities against diseases. These findings suggest the potential for acceptance of vaccines, including future HIV vaccines, among AGYW. Despite high levels of vaccine confidence, concerns over vaccine risks remain substantial and must be addressed.

27 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
NKNasimu Kyakuwa
Nasimu Kyakuwa
ASAli Ssetaala
Ali Ssetaala
MPMatt A Price
Matt A Price
Annet NanvubyaAnnet Nanvubya
Annet Nanvubya
JAJoel Muwanguzi Abyesiza
Joel Muwanguzi Abyesiza
MKMonica Kuteesa
Monica Kuteesa
Background: Vaccine hesitancy (VH) remains a major threat to global health and can reverse the progress in tackling vaccine-preventable diseases. Vaccine uptake among adolescents and young women (AGYW) is often low. We assessed VH using a validated scale among AGYW in Uganda, Zambia, and South Africa. Methods: From June 2023 to February 2024, we recruited AGYW from fishing communities in Uganda, as well as urban and peri-urban locations in Lusaka and Ndola, Zambia, and mining communities in Rustenburg, South Africa. Eligible participants were aged 15-24 years, sexually active, and HIV-negative but at-risk for HIV acquisition. We collected demographic, HIV-related behavioral data, and vaccine hesitancy data using a structured questionnaire. Vaccine confidence was assessed using the 10-question Vaccine Hesitancy Scale that describes two factors, i.e., “vaccine confidence” and “risk tolerance’’. Exploratory and confirmatory factor analyses were done to assess scale validity and internal consistency. Logistic regression was used to determine associations between demographics and VH. Results: A total of 1,213 AGYW participated in the study, with a mean age of 19.4 (SD ± 2.6) years. More than half (54%) were aged between 15-19 years. The majority of AGYW (94%) strongly believed that vaccines were important for their health and the community and that getting vaccinated is a good way to protect them from diseases. About two-thirds of the AGYW (66%) indicated that they were concerned about the adverse effects of vaccines, while 30% responded that they did not need vaccines for diseases that were not common. We observed that 951 (78%) of the AGYW reported high vaccine confidence, while 494 (41%) reported low concerns over risks. Vaccine confidence varied across countries, with Zambia and Uganda showing lower vaccine confidence (adjusted Odds Ratios of 0.28 and 0.45, respectively, p< 0.005) in comparison to South Africa. Conclusion: A high level of vaccine confidence was observed among AGYW at risk of HIV acquisition. Vaccine confidence among AGYW was driven more by the trust in vaccine safety and the need to protect communities against diseases. These findings suggest the potential for acceptance of vaccines, including future HIV vaccines, among AGYW. Despite high levels of vaccine confidence, concerns over vaccine risks remain substantial and must be addressed.